Literature DB >> 2833703

Transcriptional but not translational regulation of HIV-1 by the tat gene product.

A P Rice1, M B Mathews.   

Abstract

Human immunodeficiency virus-1 (HIV-1), which causes AIDS (acquired immune deficiency syndrome), possesses an essential gene, tat, whose product, acting through the long terminal repeat (LTR) sequences of HIV-1, activates viral genes and replication. The mechanism by which tat trans-activates HIV genes is unclear. Some studies have reported that an increase in messenger RNA accumulation directed by the HIV-1 LTR can explain the action of tat, but others suggest that this increase in mRNA levels can only partially explain trans-activation, and that translational control mechanisms may also be involved. To test those possibilities we have established an efficient adenovirus system for delivering the HIV-1 LTR attached to a reporter gene (chloramphenicol acetyltransferase; CAT) into cells and monitoring its activity. The HIV-1 LTR expressed from this adenovirus responds to trans-activation in a HeLa cell line constitutively expressing the tat protein by increasing the transcription rate of the HIV-1 LTR and the accumulation of mRNA encoding CAT. In this system the translational efficiency of this CAT mRNA in the cell is unaffected by the presence of tat.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833703     DOI: 10.1038/332551a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  60 in total

1.  Exciton interaction in molecular beacons: a sensitive sensor for short range modifications of the nucleic acid structure.

Authors:  S Bernacchi; Y Mély
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

2.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

3.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

4.  Structural analysis of wild-type and mutant human immunodeficiency virus type 1 Tat proteins.

Authors:  A P Rice; F Carlotti
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

7.  HIV Tat controls RNA Polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells.

Authors:  Jonathan E Reeder; Youn-Tae Kwak; Ryan P McNamara; Christian V Forst; Iván D'Orso
Journal:  Elife       Date:  2015-10-21       Impact factor: 8.140

8.  Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  D Harrich; J Garcia; F Wu; R Mitsuyasu; J Gonazalez; R Gaynor
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

9.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

Review 10.  Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution.

Authors:  Vanessa Rivera-Amill; Peter S Silverstein; Richard J Noel; Santosh Kumar; Anil Kumar
Journal:  J Neuroimmune Pharmacol       Date:  2009-12-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.